Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
7 February 2007
Nephrogenic Systemic Fibrosis (NSF) has been associated with some intravenous gadolinium-containing magnetic resonance imaging (MRI) contrast agents in patients with severe renal impairment.
We have issued the following documents in relation to this safety issue.
Download documents:
-
Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents: Questions and Answers (33Kb)
-
Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents: Dear Healthcare Professional Communication (173Kb)
-
Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents: Public Assessment Report (538Kb)
